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Background: The aim of this randomised pilot study was to investigate the haemodynamic effects measured by
oxygen-15 positron emission tomography (PET) of interventional treatment consisting of either endarterectomy or
endovascular treatment of stenosed cerebropetal arteries, or tapering of antihypertensive medication in comparison
with standard medical treatment alone in patients with symptomatic internal carotid artery (ICA) occlusion.
Methods: Twenty-three patients with symptomatic ICA occlusion underwent PET scanning at baseline and after
3 months. Twelve patients were randomised to intervention (either endarterectomy or endovascular treatment of
stenosed cerebropetal arteries, or tapering of antihypertensive medication) and 11 to standard medical treatment
alone. Primary outcome was a change in cerebral blood flow (CBF), cerebral blood volume (CBV) and/or oxygen
extraction fraction (OEF) after 3 months measured by PET.
Results: There were no differences in changes in CBF, CBV or OEF between the two groups. Only patients with
compromised perfusion at presentation showed a borderline significant increase in CBF of 2.8 mL/min/100 mL
(95% confidence interval 0.0 to 5.7) after intervention (n = 7).
Conclusion: This pilot study shows that in patients with symptomatic ICA occlusion, oxygen-15 PET did not detect
differences in improvement of CBF, CBV or OEF between interventional and standard treatment.
Keywords: Carotid artery diseases; Haemodynamics; Other cerebrovascular disease/stroke; PETBackground
In patients with transient ischaemic attack (TIA) or
minor disabling ischaemic stroke associated with an
occlusion of the internal carotid artery (ICA), the risk of
recurrent stroke has been reported 5% to 6% per year
[1]. This risk may be as high as 12% per year in case of a
demonstrated compromised flow to the brain [2-4]. In
these ‘high-risk’ patients, revascularization surgery may
be considered, but evidence that interventional treat-
ment reduce the risk of stroke in comparison with the* Correspondence: s.persoon@umcutrecht.nl
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in any medium, provided the original work is pstandard treatment consisting of antithrombotic medica-
tion and control of vascular risk factors is lacking.
A recent study has shown that increased oxygen ex-
traction fraction (OEF) measured by positron emission
tomography (PET) is still an independent predictor of
subsequent stroke under current medical treatment [5].
However, the Carotid Occlusion Surgery Study (COSS)
included patients with symptomatic ICA occlusion and
poor cerebral haemodynamics as demonstrated by in-
creased OEF measured by PET and found no benefit of
extracranial/intracranial (EC/IC) bypass surgery [4,6].
This trial was stopped prematurely as the 2-year risk of
ipsilateral stroke was between 20% and 25% in both
surgical and non-surgical groups (p = .78). In this study,an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Table 1 Clinical characteristics and angiographic findings
of patients with symptomatic occlusion of the internal





Age (years, mean ± SD) 68 ± 10 60 ± 12
Male 12 7
Clinical features at presentation
Cerebral TIA 9 8
Ischaemic stroke 3 3
Systolic blood pressure (mmHg, mean ± SD ) 159 ± 25 167 ± 29




Diabetes mellitus 2 3
Cigarette smoking (current or in last
5 years)
7 7
History of stroke >3 months ago 3 4
History of ischaemic heart disease 2 6
Angiogram
Contralateral ICA stenosis 50% to 69% 5 2
Stenosis 70% to 99% 1 2
Occlusion 0 1
Ipsilateral ECA stenosis ≥ 50% 4 1
Vertebral artery stenosis ≥ 50% 5 5
Collateral flow via anterior communicating
artery
12 10
Collateral flow via ophthalmic artery 5 5
Collateral flow via posterior communicating
artery
9c 11
Leptomeningeal collaterals 7d 9
aBlood pressure > 160/95 mmHg or the current use of antihypertensive
medication; bpatients with either a history of hyperlipidaemia, patients on
statins or patients with levels of total cholesterol, triglycerids or high density
lipoprotein cholesterol outside normal ranges; cthe presence of collateral flow
via the posterior communicating artery could not be judged in one patient;
dthe presence of leptomeningeal collaterals could not be judged in
two patients.
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stroke (within 30 days after surgery) was 15% [4].
Other therapeutic strategies in patients with symptom-
atic ICA occlusion aiming to improve cerebral perfusion
and reducing the risk of recurrent stroke are endarterec-
tomy or endovascular treatment of a significant stenosis
in one of the cerebropetal arteries that are part of collat-
eral pathways [2,7-10], or tapering of antihypertensive
medication [11,12].
These procedures have lower perioperative risks than
an EC/IC bypass operation, but so far, their clinical ef-
fect has not been compared to standard treatment.
Whether the application of these therapeutic strategies
improves cerebral perfusion as compared with standard
medical treatment is unclear.
The aim of this randomised pilot study was to investi-
gate the haemodynamic effects as measured by oxygen-
15 PET of endarterectomy or endovascular treatment of
stenosed cerebropetal arteries, or tapering of antihyper-
tensive medication in comparison with the standard




Between December 2004 and September 2009, patients
who had been referred to the University Medical
Center Utrecht with a symptomatic ICA occlusion were
considered for participation. Inclusion criteria were (1)
transient or at most, moderately disabling (modified
Rankin scale ≤ 3 [13]) neurological deficits associated
with ischaemia in the hemisphere ipsilateral to the ICA
occlusion, (2) ICA occlusion proven by angiograph and
(3) symptoms present within the previous 3 months.
Exclusion criteria were (1) ICA occlusion caused by
arterial dissection or radiation vasculopathy, (2) contra-
indications for magnetic resonance imaging (MRI) (claus-
trophobia or metal objects in the body) or PET (pregnancy,
blood donation in the previous 3 months or haemoglobin
concentration <8.0 mmol/L) and (3) absence of any of the
conditions that could be treated according to the thera-
peutic strategy (see below). All patients were interviewed
regarding symptoms and risk factors as listed in Table 1,
underwent neurological examination, measurement of
blood pressure and blood tests for glucose and lipids.
Contrast angiography was performed to confirm occlusion
of the ICA by absence of filling of the extracranial ICA, to
assess collateral blood supply to the symptomatic hemi-
sphere, and the presence of stenosis in the cerebropetal
arteries [14].
Patients were randomised between any intervention
according to therapeutic strategy or standard medical
treatment. In the intervention group, the therapeutic
strategy consisted of, in order of preference, one of thefollowing treatment options: (1) endarterectomy (CEA)
of the contralateral ICA in case of a severe contralateral
ICA stenosis in the presence of a functional anterior cir-
cle of Willis, (2) CEA of the external carotid artery
(ECA) in case of a severe ipsilateral ECA stenosis in the
presence of collateral blood supply via the ECA and
ophthalmic artery, (3) endovascular treatment of the
vertebral artery (VA) or subclavian artery in case of a
severely stenosed VA or subclavian artery in the pres-
ence of collaterals via the vertebrobasilar system and (4)
tapering of antihypertensive medication for 3 months. In
addition to the intervention, patients received standard
medical treatment consisting of antithrombotic medication
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sion to a targeted blood pressure of 140/90 mmHg (except
for those randomised to tapering of antihypertensive drugs)
and control of other vascular risk factors such as smoking
and obesity. To ensure equal distribution of patients with a
low CBF in both groups [15], randomisation was carried
out by minimisation for CBF in three categories (CBF ≤
33 mL/100 g/min, CBF between 34 and 53 mL/100 g/min
or CBF ≥ 54 mL/100 g/min), measured in the MCA
territory of the symptomatic hemisphere by arterial spin
labelling (ASL)-MRI [16]. The ASL-MRI scan was made
within 1 to 15 days of the baseline PET study, and included
a three-dimensional (3D) T1 image for PET image analysis.
Patients were examined by oxygen-15 PET at the time of
inclusion and 3 months thereafter. Primary outcome was a
change in CBF, CBV and/or OEF as measured by PET after
3 months. During those 3 months, we documented whether
patients had recurrent TIA or stroke, defined as an acute
onset of transient (<24 h) or permanent new focal neuro-
logical deficits of cerebral origin without haemorrhage on
CT or MRI.
The institutional medical review board approved the
study protocol, and all patients provided written in-
formed consent.PET data acquisition
Oxygen-15 PET scans were acquired using an ECAT
EXACT HR + scanner (CTI/Siemens, Knoxville, TN,
USA) [17]. Each PET study consisted of three parts: (1) a
dynamic emission scan (25 frames over 600 s) after
intravenous administration of a bolus of 1,100 MBq
[15O]H2O to measure CBF; (2) a dynamic emission scan
(20 frames over 600 s) after a 30-s net inhalation of
approximately 300 MBq [15O]O2 gas through a nasal
cannula to derive oxygen consumption and calculate
OEF; (3) an emission scan (3 frames over 360 s)
following a net inhalation of approximately 200 MBq
[15O]CO gas to measure CBV. Further details of the
scanning procedure can be found elsewhere [18].Image analysis
Individual anatomical 3D T1 MR images were co-
registered with summed [15O]H2O images. A standard tem-
plate of flow territories of middle cerebral artery (MCA),
anterior cerebral artery (ACA) and posterior cerebral artery
(PCA) [19] was warped onto the co-registered MR image
using Automated Image Registration (AIR) software [20],
applying non-rigid 12 parameter perspective warping. Stat-
istical Parametric Mapping (SPM02, London, UK, applica-
tion in Matlab 7.0.4; MathWorks, Inc., Natick, MD, USA)
was used for segmentation of grey and white matter. Areas
of infarction were excluded manually. Parametric CBF,
CBV and OEF images were generated using in-housedeveloped software (written in IDL, 6.2, ITT, Boulder CO,
USA) [21].
Data analysis
Normal CBF, CBV and OEF values were derived from 14
scans in seven healthy subjects (mean age 66 ± 7 years;
five men). They were all in a good physical and mental
condition, which had been evaluated with medical his-
tory, a physical examination and screening laboratory
tests. Subjects with a history of psychiatric or neuro-
logical illness, a Mini Mental State Examination score ≤
27 or any significant abnormality of a laboratory test
were excluded. They underwent a PET scan on two
separate occasions with a median time interval of 7 days,
as published previously [18]. CBF, CBV and OEF values
in patients were considered to be abnormal if they were
beyond mean values of normal controls ±1.96 times the
standard deviation (SD). Patients were divided into
haemodynamic stages based on their values in grey
matter of the affected MCA territory: patients with
normal CBF (≥31.1 mL/min/100 mL), normal CBV
(≤3.9 mL/100 mL) and normal OEF (≤55.7%) were clas-
sified in haemodynamic stage 0, patients with either
decreased CBF (<31.1 mL/min/100 mL) or increased
CBV (>3.9 mL/100 mL), but normal OEF in haemo-
dynamic stage 1, and patients with increased OEF
(>55.7%) in haemodynamic stage 2.
We compared mean CBF in the MCA territory of pa-
tients with data in healthy subjects [18] and calculated a
mean difference with 95% confidence interval (CI). In
the patients, differences between mean baseline grey
matter CBF, CBV and OEF values in ACA and MCA ter-
ritories of patients at baseline and after 3 months were
assessed by paired t tests with 95% confidence interval
(CI). Mean absolute change, adjusted for age and sex, in
CBF, CBV and OEF was compared between patients
assigned to intervention and those who received stand-
ard treatment using linear regression analysis, and re-
sults were expressed as adjusted mean differences in
change with 95% CI. Finally, pre-specified subgroup ana-
lyses were performed in patients with haemodynamic
stage 1 or 2 at presentation and between patients who
were randomised to treatment with surgery or stenting
of a stenosis in a collateral artery (excluding those who
had tapering of antihypertensive medication) and those
who received standard medical treatment.
Results
Complete PET data sets were obtained for 23 patients
(mean age 64 ± 11 years; 19 men). Of 41 eligible patients,
14 failed to complete the initial PET study and were ex-
cluded and four others did not complete the PET study
after 3 months (Figure 1). Twelve patients were assigned
to intervention (eight stenting or surgery and four
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standard treatment. Clinical characteristics and presence
of stenosis in cerebropetal arteries and collateral path-
ways are shown in Table 1. Twenty-two patients had had
recurrent ischaemic symptoms after the ICA occlusion
had been demonstrated, but before inclusion in the
study. The time between last symptoms and first PET
scan was on average 38 ± 23 days in both treatment
groups. At baseline, ten patients were characterized as
haemodynamic stage 0, 11 as stage 1 and two as stage 2.
Figure 2 shows parametric images of a typical patient
with stage 2 haemodynamic failure. Patients with a
symptomatic ICA occlusion had a mean CBF in the
ipsilateral MCA territory of 32.2 ± 5.6, which was signifi-
cantly lower (mean difference −5.2 mL/min/100 mL,
95% CI −9.8 to −0.6) than that in healthy subjects (mean
CBF MCA territory of 37.4 ± 3.2) [18].
The mean time between PET scans at baseline and
follow-up was 98 ± 10 (range 77 to 119) days. All pa-
tients were treated according to their randomisation.
Randomisation occurred on average 5 ± 9 days after the
baseline PET scan. Of the 12 patients assigned to inter-
vention (Figure 1), eight patients underwent stenting or
surgery after a mean time of 15 ± 10 (range 1 to 29) days
following the baseline PET scan. In four patients, antihy-
pertensive medication was tapered, which resulted in a
mean increase in systolic blood pressure of 38 ± 9 mmHg.
Intervention was complicated by a non-fatal myocardial
infarction in one patient who underwent CEA of a
contralateral ICA stenosis; none of the procedures were
complicated by a stroke or hyperperfusion syndrome.Figure 1 Trial profile. CEA, carotid endarterectomy; ICA, internal carotid arteryMean values of CBF, CBV and OEF were similar at base-
line and after 3 months, both in patients treated with inter-
vention and in those assigned to standard treatment
(Table 2), but CBF changes varied in individual patients
(Figure 3). No differences in absolute CBF, CBV and OEF
changes after 3 months were observed between patients
assigned to intervention and those assigned to standard
treatment (Table 2).
Of the ten patients with normal CBF, CBV and OEF at
baseline (haemodynamic stage 0), five underwent interven-
tional treatment (CEA of the contralateral ICA in one,
CEA of the ipsilateral ECA in one, stenting of the VA in
one, and tapering of antihypertensive medication in two pa-
tients), which did not result in a further increase in CBF in
the MCA territory (mean difference −3.1, 95% CI −13.1 to
6.9, Table 3). Of the 13 patients with haemodynamic com-
promise (haemodynamic stage 1 or 2), five underwent
stenting or surgery (CEA of the contralateral ICA in two,
CEA of the ipsilateral ECA in one, and stenting of the VA
in two patients), in two, the antihypertensive medication
was tapered and six received standard treatment. The seven
patients assigned to intervention had a mean CBF in the
MCA territory of 27.2 ± 3.4 mL/min/100 mL at baseline,
which increased to 30.0 ± 3.9 mL/min/100 mL after
3 months (mean difference 2.8 mL/min/100 mL, 95% CI
0.0 to 5.7). The mean increase in CBF in the MCA territory
in patients treated by intervention was, however, not signifi-
cantly different from the increase in CBF in patients who
received standard treatment (Table 3). Mean CBV in the
MCA territory in patients with haemodynamic compromise
treated with an intervention showed a small non-significant; ECA, external carotid artery; VA, vertebral artery; SA, subclavian artery.
Figure 2 Parametric images of a patient with stage 2 haemodynamic failure. This 69-year-old man presented with a minor ischaemic stroke
(without infarction on his MRI) and recurrent TIAs from the left hemisphere associated with a left ICA occlusion. The baseline PET study showed
decreased cerebral blood flow (CBF) and increased oxygen extraction fraction (OEF) in the territories of both anterior and middle cerebral artery
of the left hemisphere. This patient was randomised for tapering of antihypertensive medication. The PET study after 3 months showed a slight
improvement in CBF and OEF. However, he still had recurrent TIAs in the presence of stage 2 haemodynamic failure.
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tients who received standard treatment (Table 3). Because
only two patients had an increased OEF at baseline, the
effect of intervention on mean OEF after 3 months could
not be formally compared. One of the two patients was
assigned to standard treatment and after 3 months OEF
was unchanged. In the other patient antihypertensive medi-
cation was tapered and OEF decreased from 72% to 66%
after 3 months.
The eight patients treated with surgery or stenting of a
stenosis in a collateral artery had a mean CBF of 30.8 ±
5.4 mL/min/100 mL at baseline and 31.8 ± 5.2 mL/min/
100 mL after 3 months (mean difference 0.97, 95%
CI −4.6 to 6.6). In the 11 patients who received standard
medical treatment alone, mean CBF was 33.1 ± 5.4 mL/
min/100 mL at baseline and 33.5 ± 4.7 mL/min/100 mL
after 3 months (mean difference 0.42, 95% CI −2.4 to
3.2). The change in CBF did not differ between these
two groups of patients (adjusted mean difference of
change −0.02 mL/min/100 mL, 95% CI −7.2 to 7.1).
Clinical outcome
During the period between PET scans at baseline and
after 3 months, 10 (43%) of 23 patients had one or more
recurrent TIAs and none had a stroke. At baseline, five
of the ten patients were in haemodynamic stage 0, threein haemodynamic stage 1, and two in haemodynamic
stage 2. Two of the eight patients (25%) who underwent
CEA or stenting, three of the four (75%) who had tapering
of antihypertensive medication and 5 of the 11 (45%) who
received standard medical treatment had one or more re-
current TIAs during the 3 months follow-up period be-
tween PET scans at baseline and after 3 months. Clinical
follow-up continued with an overall median duration of
2.9 (range 0.5 to 4.4) years. Three of the 23 patients (13%)
had a recurrent ischaemic stroke during follow-up.
The first patient experienced multiple TIAs and a
minor ischaemic stroke (modified Rankin scale 2) in the
hemisphere ipsilateral to the ICA occlusion 47 days after
CEA of the contralateral ICA. The second patient had
been treated with CEA of the ipsilateral ECA. In this pa-
tient, CBF was 37.1 mL/min/100 mL at baseline, which
deteriorated to 26.6 mL/min/100 mL after 3 months.
Because of ongoing TIAs, he also underwent CEA of the
contralateral ICA 5 months after the 3-month PET scan.
Nine months later, he had a fatal ischaemic stroke in the
hemisphere ipsilateral to the ICA occlusion. The third
patient was randomised for standard treatment (not ta-
pering antihypertensive medication). In this patient, CBF
was 32.3 mL/min/100 mL at baseline, deteriorating to
28.5 mL/min/100 mL after 3 months. He continued to
have TIAs during the period between the two PET scans
Table 2 Comparison of haemodynamic state of the brain at baseline and after 3 months between patients assigned to intervention and those to standard
treatment (n = 23)
Intervention n = 12 Standard n = 11 Unadjusted difference
in change (95% CI)
Adjusted difference
in change* (95% CI)Mean ± SD Mean ± SD
CBF MCA (mL/min/100 mL) Baseline 31.3 ± 5.9 33.1 ± 5.4
3 months 31.6 ± 4.9 33.5 ± 4.7
Change 0.34 ± 6.2 0.42 ± 4.1 −0.1 (−4.7 to 4.5) −1.0 (−7.4 to 5.4)
CBF ACA (mL/min/100 mL) Baseline 32.6 ± 5.8 35.2 ± 5.5
3 months 32.0 ± 4.2 35.0 ± 5.7
Change −0.56 ± 6.2 −0.28 ± 4.9 −0.3 (−5.2 to 4.6) −1.6 (−8.4 to 5.2)
CBV MCA (mL/100 mL) Baseline 3.0 ± 0.6 3.3 ± 0.9
3 months 3.5 ± 1.4 3.2 ± 0.6
Change 0.60 ± 1.7 −0.09 ± 1.2 0.7 (−0.6 to 2.0) 0.09 (−1.7 to 1.9)
CBV ACA (mL/100 mL) Baseline 3.0 ± 0.6 3.4 ± 1.0
3 months 3.5 ± 1.3 3.1 ± 0.7
Change 0.49 ± 1.6 −0.23 ± 1.3 0.7 (−0.6 to 2.0) 0.08 (−1.6 to 1.8)
OEF MCA (%) Baseline 46.4 ± 9.7 47.5 ± 5.5
3 months 46.3 ± 7.9 48.4 ± 5.8
Change −0.08 ± 6.1 0.85 ± 6.8 −0.9 (−6.5 to 4.7) 3.1 (−4.1 to 10.3)
OEF ACA (%) Baseline 44.4 ± 11.2 46.1 ± 6.2
3 months 44.2 ± 7.3 47.2 ± 5.2
Change −0.17 ± 7.4 1.1 ± 6.3 −1.3 (−7.3 to 4.7) 3.1 (−4.6 to 10.8)
Asterisk ‘*’ indicates adjusted for age and sex; measurements were performed ipsilateral to the side of the ICA occlusion; CBF, cerebral blood flow; CBV, cerebral blood volume; OEF, oxygen extraction fraction; MCA,





































































































Figure 3 CBF changes over time in the MCA territory for individual patients. Patients randomised to (A) CEA of a contralateral ICA stenosis,
(B) CEA of an ipsilateral ECA stenosis, (C) angioplasty and stent placement of a VA stenosis and (D) tapering of antihypertensive medication.
Patients randomised to intervention are indicated by continuous lines and patients randomised to standard treatment by dashed lines.
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bypass operation 9 months after randomization. Three
months thereafter, he had a fatal ischaemic stroke in the
hemisphere contralateral to the ICA occlusion.
Discussion
This study shows that patients with recent symptoms of
cerebral ischaemia associated with occlusion of the ICA on
average have a lower CBF in the hemisphere ipsilateral to
the occlusion than healthy subjects. Oxygen-15 PET showed
that interventions aimed at improving cerebral perfusion
caused a borderline significant increase in CBF in patients
who had an impaired haemodynamic state of the brain at
presentation, but improvement in CBF was not different
between interventional and standard treatment.
Current knowledge of cerebral haemodynamic and
metabolic changes over time in medically treated patients
with an ICA occlusion is based on small patient series,
and both improvement and deterioration over time have
been described. In one study, ten medically treated pa-
tients with symptomatic ICA occlusion and increased
OEF underwent a second PET scan after 12 to 59 months
[22]. Over time, patients showed on average an increase in
CBF hemispheric (ipsilateral/contralateral) ratio and a de-
crease in OEF hemispheric ratio, but without changes inabsolute values of CBF and OEF [22]. Another study of
seven patients with symptomatic ICA occlusion and nor-
mal CBF and OEF at baseline found a significant decrease
in CBF and increase in OEF after 24 to 64 months, impli-
cating haemodynamic deterioration over time [23]. Other
studies reported a bilateral increase in cerebrovascular re-
activity measured by Transcranial Doppler (TCD) after
CEA of a contralateral carotid stenosis in the presence of
a symptomatic or asymptomatic ICA occlusion [9,10,24].
In contrast to these studies, we did not find a significant
effect of treatment aimed at improving the flow state of
the brain when compared to control patients in a rando-
mised design. A possible explanation could be that the
cerebral haemodynamic state also improved without
intervention. Patients with haemodynamic compromise
at baseline who received standard treatment showed a
small non-significant increase in CBF. It has been
shown before that patients with ICA occlusion and a
compromised flow state of the brain may improve spon-
taneously over time [25]. In addition, in patients with a
normal haemodynamic state of the brain (stage 0) at
baseline who underwent an intervention, particularly
those treated by tapering of antihypertensive medica-
tion, a further increase in CBF may not be expected be-
cause of preserved cerebral autoregulation.
Table 3 Mean CBF and CBV for patients with symptomatic ICA occlusion, classified in haemodynamic stage 0 (n = 10) and haemodynamic stage 1 or 2 (n = 13)
Intervention Standard Unadjusted difference
in change (95% CI)
Adjusted difference
in change* (95% CI)Mean ± SD Mean ± SD
Haemodynamic stage 0 N = 5 N = 5
CBF MCA (mL/min/100 mL) Baseline 37.0 ± 3.0 35.0 ± 5.6
3 months 33.9 ± 5.8 34.4 ± 5.2
Change −3.1 ± 8.1 −0.6 ± 5.3 −2.5 (−12.5 to 7.4) −1.7 (−15.6 to 12.2)
CBV MCA (mL/100 mL) Baseline 3.1 ± 0.6 2.8 ± 0.7
3 months 3.0 ± 0.7 3.5 ± 0.4
Change −0.2 ± 1.1 0.6 ± 1.0 −0.8 (−2.3 to 0.7) −1.1 (−3.2 to 1.1)
Haemodynamic stage 1 or 2 N = 7 N = 6
CBF MCA (mL/min/100 mL) Baseline 27.2 ± 3.4 31.5 ± 5.2
3 months 30.0 ± 3.9 32.8 ± 4.6
Change 2.8 ± 3.1 1.3 ± 3.2 1.6 (−2.2 to 5.4) −1.1 (−7.8 to 5.7)
CBV MCA (mL/100 mL) Baseline 2.9 ± 0.6 3.7 ± 0.8
3 months 4.0 ± 1.7 3.0 ± 0.6
Change 1.1 ± 1.9 −0.7 ± 1.1 1.8 (−0.2 to 3.8) 1.4 (−2.4 to 5.1)
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did not select patients on the basis of demonstrated
cerebral haemodynamic compromise. The design of the
study was aimed at including patients at high risk of re-
current stroke by selection on clinical criteria: ischaemic
symptoms of the brain after documented occlusion, ex-
cluding patients with eye symptoms alone and those
with symptoms only before the ICA occlusion were doc-
umented without ongoing symptoms thereafter [26]. We
had expected that these clinical criteria would have re-
sulted in a much larger proportion of patients with
haemodynamic stages 1 and 2. Because the average time
between the last symptoms of patients and the baseline
PET scan was 38 days, spontaneous improvement of a
compromised flow state of the brain may have occurred
before the PET scan took place. This may have contrib-
uted to the lack of a difference between the PET scan at
baseline and after 3 months.
Another limitation might be heterogeneity in treating
patients assigned to intervention. We have chosen for
this randomization scheme rather than designing separ-
ate studies for each of the treatment options because all
treatment options aim to improve cerebral perfusion.
However, effects of tapering of antihypertensive medica-
tion on the haemodynamic state of the brain may well
be different from those of surgery or stenting of sten-
osed arteries that may be important for collateral blood
supply. Subgroup analysis of the present data comparing
surgery or stenting of a stenosis in the contralateral
ICA, ipsilateral ECA or VA with standard medical treat-
ment alone did not show significant differences in CBF,
but the number of patients in each group was small.
Likewise, effects of surgery or stenting of the contralat-
eral ICA on cerebral perfusion may be different than
those of surgery or stenting of the ipsilateral ECA or
VA. Furthermore, it has been described that both end-
arterectomy and stenting can be complicated by a hyper-
perfusion syndrome [27], but in none of the patients,
this complication occurred.
The third limitation is that a relatively high number of
patients had to be excluded because they did not have
two successfully performed PET studies. Our failure rate
was similar to the rate of 22% for quantitative studies in
the St Louis Study [3,6], and lower than in another PET
study that reported a failure rate of 41% [28]. Finally, the
sample size in our study was probably too small to
detect differences between the two treatment strategies
except when they were large.
Conclusions
Although the results of this pilot study are not conclusive,
some important lessons can be learned. Patients with
TIA or ischaemic stroke in the hemisphere ipsilateral
to the ICA occlusion are at risk of subsequent cerebralischaemia. In these patients with symptomatic ICA occlu-
sion, the clinical benefit of CEA or endovascular treat-
ment of an additional stenosis in the cerebropetal arteries
or tapering of antihypertensive medication has not been
shown by a randomised trial. The recently published re-
sults of the Carotid Occlusion Surgery Study randomised
trial [4] that showed no benefit of STA-MCA bypass sur-
gery over medical treatment despite improvement of cere-
bral haemodynamics in the surgical group reinforce the
need for other therapies to improve outcome in patients
with ICA occlusion at high risk of recurrent stroke.
Oxygen-15 PET is useful to identify a subgroup of patients
with haemodynamic compromise, but we could not dem-
onstrate that stenting or surgery of stenosed cerebropetal
arteries or tapering of antihypertensive medication im-
proved the haemodynamic state of the brain to a large ex-
tent in comparison with standard treatment. Whether
revascularization of collaterals or tapering of antihyperten-
sive medication can reduce the risk of recurrent stroke
can only be determined in a large randomised trial of pa-
tients with a symptomatic ICA occlusion at high risk of
stroke.
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